Seno gets $2m in state funding:
This article was originally published in Clinica
Opto-acoustic technology specialist Seno Medical Instruments has been awarded $2m from the Texas Emerging Technology Fund (TETF), a $200m government investment programme aimed at financing local advancing technology projects. This investment allows San Antonio, Texas-based Seno to further develop its breast cancer imaging technology, and work towards implementing initial clinical trials on technology at the Cancer Therapy and Research Center, and the University of Texas Health Science Center. The company is aiming to provide a device that uses optics and acoustics, instead of x-ray radiation, to capture an accurate image of a tumour.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.